01572nas a2200229   4500000000100000008004100001260001000042653002000052653002200072653002700094653001600121100002000137700001400157700001600171700001400187245007700201856005200278300000800330490000700338520098300345022001401328       2024                            d  bLepra10aG6PD deficiency10achildhood leprosy10aborderline tuberculoid10aROM regimen1 aRusmawardiana R1 aPamudji R1 aArgentina F1 aAldona WS00aG6PD deficiency in childhood borderline tuberculoid leprosy: A rare case  uhttps://leprosyreview.org/article/95/2/20-24020  a1-50 v953 a<p>Glucose-6-phosphate dehydrogenase (G6PD) deficiency is known to cause haemolysis in patients with leprosy receiving multidrug therapy (MDT) containing dapsone. Dapsone releases N-hydroxy metabolites that can cause hemolytic anemia and hyperbilirubinemia. Concomitant G6PD significantly increases the risk of severe intravascular hemolysis. Severe hemolysis can cause mortality in children. It is crucial to be aware before the diagnosis of leprosy because it determines the treatment. Rifampicin, ofloxacin and minocycline (ROM) regimen are indicated as alternative treatment. Childhood leprosy with G6PD deficiency is a rare disease, and it is infrequently tested. A G6PD test should be standard procedure for all institutions before starting MDT, because it can be helpful in reducing the occurrence of haemolytic complications. We report a case of a 14-year-old Indonesian boy with borderline tuberculoid leprosy who was on monthly ROM regimen with good improvement.</p>
  a2162-8807